PubMed
MK-677, an orally active growth hormone secretagogue: effects on body composition
Murphy et al., 1998
GH SecretagoguesResearch OnlyB
MK-677
Ibutamoren
Oral ghrelin receptor agonist used in GH-axis research.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 99
- Activity
- 76
Overall check-ins
Trackers & reports
Overview
About MK-677
Oral ghrelin receptor agonist used in GH-axis research.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Ibutamoren
- Self-reports
- 24
Community
What 24 users report
24 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
135
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Fatigue
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
135
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 156 days · Based on 22 repeat reporters
Research
Cited research (5)
Source
PubMed
Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life
Nass et al., 2008
ClinicalTrials.gov
Ibutamoren (MK-677) studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy et al., 1998
PubMed
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control
Philip et al., 2022
Tools
Explore more
Explore
More ways to learn about MK-677 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about MK-677?
This page summarizes 24 anonymized self-reports from PeptIQ users who track MK-677, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for MK-677?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for MK-677?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is MK-677 safe to use?
This wiki does not assess safety or recommend use. MK-677 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of MK-677?
This wiki summarizes observational community reports and linked citations for MK-677. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for MK-677 for study-level context — not medical advice.
What is the legal status of MK-677?
MK-677 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of MK-677?
Safety data quality for MK-677 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on MK-677?
This page links 5 indexed sources for MK-677. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.